Sara Martinez‐Ramos
Research Subjects
Sara Martinez‐Ramos has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
- Samuel García
Research Laboratory and Rheumatology Unit, Hospital Clínico Universitario de Santiago de Compostela, Spain
2 shared publications Alberto Rivera
Department of Internal Medicine University Hospital Complex of Vigo Vigo Spain
1 shared publicationAna Argibay
Department of Internal Medicine University Hospital Complex of Vigo Vigo Spain
1 shared publicationAna Pinheiro‐Lopes
Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht University of Utrecht Utrecht The Netherlands
1 shared publicationAngela Rodriguez-Trillo
Laboratorio de Reumatología Experimental y Observacional, Servicio de Reumatología, Instituto de Investigación Sanitaria de Santiago (IDIS), Hospital Clínico, Universitario de Santiago de Compostela (CHUS), Servizo Galego de Saude (SERGAS) , Santiago de Compostela, Spain
1 shared publicationArjan van Caam
Department of Rheumatology, Radboudumc Nijmegen the Netherlands
1 shared publication
Latest Publications
- Open Access
- 20 October 2026
- Published by Wiley in Arthritis & Rheumatology
Sema4A neutralization reduces fibrosis and inflammation in a mouse model of systemic sclerosis and a 3D model of immunity‐driven fibrosis
Objective: We previously showed that Semaphorin4A (Sema4A) is elevated in patients with systemic sclerosis (SSc) and promotes inflammation and fibrosis in vitro . Here, we examined the effect of Sema4A neutralization in vivo and in 3D fibrosis models. Methods: Sema4A plasma levels were measured by ELISA in healthy controls (n=31) and patients with SSc (n=30). In the bleomycin SSc‐model, mice were treated with an anti‐Sema4A neutralizing antibody or its respective isotype control (n=6‐7). The 3D fibrosis models, consisting of collagen hydrogel, dermal fibroblasts, and peripheral blood mononuclear cells, were stimulated with recombinant Sema4A, rapamycin, or antibodies neutralizing Sema4A, PlexinD1, PlexinB2, Neuropilin‐1 or their respective isotype controls (n=6‐10). Collagen content was determined by trichrome staining and hydroxyproline assay. Gene expression was determined by RT‐qPCR and obtained from GEO‐NCBI expression arrays, while protein expression by immunohistochemistry, immunoblotting and flow cytometry. Results: Circulating Sema4A was elevated in patients with SSc (p<0.0001), while Sema4A receptors were elevated in SSc skin and lung (p ranged from <0.05 to 0.0001). Anti‐Sema4A administration significantly reduced skin and lung collagen content in bleomycin‐treated mice (p<0.01), as well as the expression of extracellular matrix components, fibrotic and inflammatory mediators, and immune cell infiltration. In the 3D models, SSc serum and SSc PBMCs induced cell contraction, which was drastically abrogated by blocking Sema4A (p<0.01). This effect was associated with reduced expression of fibrotic mediators and attenuated mTORC1 pathway activation. Conclusions: We confirmed the pro‐fibrotic and pro‐inflammatory role of Sema4A, postulating Sema4A neutralization as a novel approach for the treatment of SSc.
- 20 October 2026
- Published by Wiley in Arthritis & Rheumatology
Open AccessSema4A neutralization reduces fibrosis and inflammation in a mouse model of systemic sclerosis and a 3D model of immunity‐driven fibrosis
Objective: We previously showed that Semaphorin4A (Sema4A) is elevated in patients with systemic sclerosis (SSc) and promotes inflammation and fibrosis in vitro . Here, we examined the effect of Sema4A neutralization in vivo and in 3D fibrosis models. Methods: Sema4A plasma levels were measured by ELISA in healthy controls (n=31) and patients with SSc (n=30). In the bleomycin SSc‐model, mice were treated with an anti‐Sema4A neutralizing antibody or its respective isotype control (n=6‐7). The 3D fibrosis models, consisting of collagen hydrogel, dermal fibroblasts, and peripheral blood mononuclear cells, were stimulated with recombinant Sema4A, rapamycin, or antibodies neutralizing Sema4A, PlexinD1, PlexinB2, Neuropilin‐1 or their respective isotype controls (n=6‐10). Collagen content was determined by trichrome staining and hydroxyproline assay. Gene expression was determined by RT‐qPCR and obtained from GEO‐NCBI expression arrays, while protein expression by immunohistochemistry, immunoblotting and flow cytometry. Results: Circulating Sema4A was elevated in patients with SSc (p<0.0001), while Sema4A receptors were elevated in SSc skin and lung (p ranged from <0.05 to 0.0001). Anti‐Sema4A administration significantly reduced skin and lung collagen content in bleomycin‐treated mice (p<0.01), as well as the expression of extracellular matrix components, fibrotic and inflammatory mediators, and immune cell infiltration. In the 3D models, SSc serum and SSc PBMCs induced cell contraction, which was drastically abrogated by blocking Sema4A (p<0.01). This effect was associated with reduced expression of fibrotic mediators and attenuated mTORC1 pathway activation. Conclusions: We confirmed the pro‐fibrotic and pro‐inflammatory role of Sema4A, postulating Sema4A neutralization as a novel approach for the treatment of SSc.
- Open Access
- 18 November 2022
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 62 (7) , 2621-2630
HOXA5 is a key regulator of class 3 semaphorins expression in the synovium of rheumatoid arthritis patients
Class 3 semaphorins are reduced in the synovial tissue of RA patients and these proteins are involved in the pathogenesis of the disease. The aim of this study was to identify the transcription factors involved in the expression of class 3 semaphorins in the synovium of RA patients. Protein and mRNA expression in synovial tissue from RA and individuals at risk (IAR) patients, human umbilical vein endothelial cells (HUVEC) and RA fibroblast-like synoviocytes (FLS) was determined by ELISA, immunoblotting and quantitative PCR. TCF-3, EBF-1 and HOXA5 expression was knocked down using siRNA. Cell viability, migration and invasion were determined using MTT, calcein, wound closure and invasion assays, respectively. mRNA expression of all class 3 semaphorins was significantly lower in the synovium of RA compared with IAR patients. In silico analysis suggested TCF-3, EBF-1 and HOXA5 as transcription factors involved in the expression of these semaphorins. TCF-3, EBF-1 and HOXA5 silencing significantly reduced the expression of several class 3 semaphorin members in FLS and HUVEC. Importantly, HOXA5 expression was significantly reduced in the synovium of RA compared with IAR patients and was negatively correlated with clinical disease parameters. Additionally, TNF-α down-regulated the HOXA5 expression in FLS and HUVEC. Finally, HOXA5 silencing enhanced the migratory and invasive capacities of FLS and the viability of HUVEC. HOXA5 expression is reduced during the progression of RA and could be a novel therapeutic strategy for modulating the hyperplasia of the synovium, through the regulation of class 3 semaphorins expression.
- 18 November 2022
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 62 (7) , 2621-2630
Open AccessHOXA5 is a key regulator of class 3 semaphorins expression in the synovium of rheumatoid arthritis patients
Class 3 semaphorins are reduced in the synovial tissue of RA patients and these proteins are involved in the pathogenesis of the disease. The aim of this study was to identify the transcription factors involved in the expression of class 3 semaphorins in the synovium of RA patients. Protein and mRNA expression in synovial tissue from RA and individuals at risk (IAR) patients, human umbilical vein endothelial cells (HUVEC) and RA fibroblast-like synoviocytes (FLS) was determined by ELISA, immunoblotting and quantitative PCR. TCF-3, EBF-1 and HOXA5 expression was knocked down using siRNA. Cell viability, migration and invasion were determined using MTT, calcein, wound closure and invasion assays, respectively. mRNA expression of all class 3 semaphorins was significantly lower in the synovium of RA compared with IAR patients. In silico analysis suggested TCF-3, EBF-1 and HOXA5 as transcription factors involved in the expression of these semaphorins. TCF-3, EBF-1 and HOXA5 silencing significantly reduced the expression of several class 3 semaphorin members in FLS and HUVEC. Importantly, HOXA5 expression was significantly reduced in the synovium of RA compared with IAR patients and was negatively correlated with clinical disease parameters. Additionally, TNF-α down-regulated the HOXA5 expression in FLS and HUVEC. Finally, HOXA5 silencing enhanced the migratory and invasive capacities of FLS and the viability of HUVEC. HOXA5 expression is reduced during the progression of RA and could be a novel therapeutic strategy for modulating the hyperplasia of the synovium, through the regulation of class 3 semaphorins expression.